Variety

MULTICENTER OBSERVATIONAL STUDY

VARIETY Study

A prospective, non-interventional observational study of patients with inflammatory bowel disease (IBD)
receiving vedolizumab subcutaneously or intravenously to observe the choice
of administration route and treatment outcomes (VARIETY)

Variety

Dear Sir/Madam,

We invite you to participate in a multicenter observational study entitled:

"A prospective, non-interventional observational study of patients with inflammatory bowel disease (IBD) receiving vedolizumab subcutaneously or intravenously to observe the choice of administration route and treatment outcomes (VARIETY)"

To begin the study, it is necessary to sign an online agreement, so please register and follow the instructions that appear on the computer screen.

Please complete the registration form
and join the study

Registration form

CRO

BioStat Sp. z o.o.
Kowalczyka 17, 44-206 Rybnik
phone: 530 714 118
email: [email protected]

BioStat CBR
Sponsor

Takeda Pharma Sp. z o.o.
Prosta 68, 00-838 Warsaw
phone: +48 608 13 00/01
fax: +48 22 608 13 03

Takeda